Amphastar Pharmaceuticals, Inc (AMPH) Dividends

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 2,028 full-time employees. The company went IPO on 2014-06-25. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The firm manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The firm manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.